PMID- 29848902
OWN - NLM
STAT- MEDLINE
DCOM- 20181114
LR  - 20221207
IS  - 1348-4540 (Electronic)
IS  - 0918-8959 (Linking)
VI  - 65
IP  - 7
DP  - 2018 Jul 28
TI  - Improved cardiometabolic risk factors in Japanese patients with type 2 diabetes 
      treated with ipragliflozin: a pooled analysis of six randomized, 
      placebo-controlled trials.
PG  - 693-705
LID - 10.1507/endocrj.EJ17-0491 [doi]
AB  - To examine differential improvements among cardiovascular risk factors in 
      response to treatment with ipragliflozin in Japanese type 2 diabetes mellitus 
      (T2DM) patients, we conducted a pooled analysis of six randomized, double-blind 
      trials of Japanese T2DM patients who received ipragliflozin 50 mg/day or placebo 
      and had patient-level data for cardiometabolic risk parameters. Risk factors 
      included glycated hemoglobin (HbA1c), body weight, homeostatic model assessment 
      for insulin resistance and beta-cell function (HOMA-R and HOMA-beta, 
      respectively), systolic blood pressure, fasting serum insulin concentrations, and 
      the concentration of uric acid, lipids, and liver enzymes from baseline to end of 
      treatment (EOT; 12-24 weeks). The primary endpoint of each trial was the change 
      in HbA1c from baseline to EOT. Changes in risk factors from baseline to EOT were 
      compared between ipragliflozin-treated and placebo groups, and between two 
      subgroups (high- and low-risk groups for each parameter). All parameters, except 
      low-density lipoprotein cholesterol (LDL-C) and non high-density lipoprotein 
      cholesterol (non HDL-C), improved significantly in the ipragliflozin group. 
      Subgroup analysis revealed a significantly greater improvement in the high-risk 
      group versus low-risk group in HbA1c, HOMA-R, HOMA-beta, aspartate transaminase, 
      alanine transaminase, and gamma-glutamyltransferase, but not in any of the lipid 
      parameters or blood pressure. Liver function improvement in the ipragliflozin 
      group was significantly correlated with changes in body weight, HbA1c, HOMA-beta, 
      and HOMA-R. This analysis demonstrated that, in Japanese T2DM patients, 
      ipragliflozin 50 mg/day was associated with improvements in cardiometabolic risk 
      factors, except for LDL-C and non HDL-C.
FAU - Kashiwagi, Atsunori
AU  - Kashiwagi A
AD  - Kusatsu General Hospital, Kusatsu, Shiga 525-8585, Japan.
FAU - Sakatani, Taishi
AU  - Sakatani T
AD  - Astellas Pharma Inc., Chuo-ku, Tokyo 103-8411, Japan.
FAU - Nakamura, Ichiro
AU  - Nakamura I
AD  - Astellas Pharma Inc., Chuo-ku, Tokyo 103-8411, Japan.
FAU - Akiyama, Noriko
AU  - Akiyama N
AD  - Astellas Pharma Inc., Chuo-ku, Tokyo 103-8411, Japan.
FAU - Kazuta, Kenichi
AU  - Kazuta K
AD  - Astellas Pharma Inc., Chuo-ku, Tokyo 103-8411, Japan.
FAU - Ueyama, Eiji
AU  - Ueyama E
AD  - Astellas Pharma Inc., Chuo-ku, Tokyo 103-8411, Japan.
FAU - Takahashi, Hideyuki
AU  - Takahashi H
AD  - Astellas Pharma Inc., Chuo-ku, Tokyo 103-8411, Japan.
FAU - Kosakai, Yoshinori
AU  - Kosakai Y
AD  - Astellas Pharma Inc., Chuo-ku, Tokyo 103-8411, Japan.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20180529
PL  - Japan
TA  - Endocr J
JT  - Endocrine journal
JID - 9313485
RN  - 0 (Blood Glucose)
RN  - 0 (Glucosides)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Thiophenes)
RN  - 3N2N8OOR7X (ipragliflozin)
SB  - IM
MH  - Aged
MH  - Blood Glucose/analysis
MH  - Body Mass Index
MH  - Cardiovascular Diseases/*etiology
MH  - Diabetes Mellitus, Type 2/complications/*drug therapy
MH  - Double-Blind Method
MH  - Female
MH  - Glucosides/*therapeutic use
MH  - Glycated Hemoglobin/analysis
MH  - Humans
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Insulin Resistance
MH  - Japan
MH  - Male
MH  - Middle Aged
MH  - Risk Factors
MH  - Thiophenes/*therapeutic use
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Cardiometabolic risk factors
OT  - Ipragliflozin
OT  - Liver function
OT  - Pooled analysis
OT  - Type 2 diabetes mellitus
EDAT- 2018/06/01 06:00
MHDA- 2018/11/15 06:00
CRDT- 2018/06/01 06:00
PHST- 2018/06/01 06:00 [pubmed]
PHST- 2018/11/15 06:00 [medline]
PHST- 2018/06/01 06:00 [entrez]
AID - 10.1507/endocrj.EJ17-0491 [doi]
PST - ppublish
SO  - Endocr J. 2018 Jul 28;65(7):693-705. doi: 10.1507/endocrj.EJ17-0491. Epub 2018 
      May 29.